The ARHGAP23 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, offering a loss-of-function model for the Rho GTPase-activating protein ARHGAP23. This pool of knockout cells provides a heterogeneous genetic background suitable for studying the impact of ARHGAP23 disruption without the biases of clonal selection.
The HT29 cell line, established from a primary colon adenocarcinoma of a female patient, is a widely used model for colorectal cancer research. It carries a BRAF V600E mutation, a TP53 mutation, and displays epithelial morphology with the ability to form polarized monolayers. These features make HT29 a relevant host for investigating genes involved in colorectal cancer progression.
ARHGAP23 encodes a RhoGAP that negatively regulates Rho family GTPases, primarily RhoA, Rac1, and Cdc42, by enhancing GTP hydrolysis. This activity dampens downstream signaling through ROCK, LIMK, and the ARP2/3 complex, thereby controlling actin cytoskeleton remodeling, stress fiber assembly, and focal adhesion maturation. Upstream, ARHGAP23 is regulated by integrin-mediated adhesion, growth factor receptors such as EGFR and TGF??, and mechanical cues, with transcriptional input from SRF/MRTF complexes. Key downstream targets include focal adhesion kinase (FAK), paxillin, and the adaptors vinculin and talin, all of which mediate cell?Cextracellular matrix adhesion and migration.
In the HT29 background, knockout of ARHGAP23 is predicted to unleash Rho GTPase signaling, promoting sustained actin polymerization, enhanced focal adhesion dynamics, and increased cell motility. These changes, which favor invasive behavior, are highly relevant to colorectal cancer metastasis and epithelial?Cmesenchymal transition. Thus, this knockout model is instrumental for exploring how loss of ARHGAP23-mediated GTPase suppression contributes to tumor cell dissemination in the context of a clinically relevant genotype.
Typical research uses include Western blotting for ARHGAP23 and Rho pathway proteins, Rho activation assays (G-LISA, pull-down), wound healing assays, Transwell migration/invasion assays, and immunofluorescence for F-actin and focal adhesions. The cells are also suited for 3D spheroid invasion models and pharmacological testing with ROCK inhibitors or other Rho pathway modulators. For specific inquiries or ordering information, please contact Ascent Research.
